Mark Rohrbaugh, a mid-level staffer at the National Institutes of Health, has consistently blocked the use of march-in rights to seize patents on high-cost drugs.
corporate power
Posted inWorking in America
Chipmaker’s Scramble to Build Marred by Mistakes and Injuries
TSMC’s $40 billion semiconductor facility in Phoenix, an open shop that resisted signing an agreement with labor unions, has been tainted with accidents, alleged wage theft, and costly setbacks.
Posted inBooks, Arts and Culture
Drowned in the Stream
Hard-hitting filmmaker Amy Ziering on why journalistic documentaries are facing extinction
Posted inEconomic Policy
A Return to Rentiership
A new paper shows that rent-seeking by firms with dominant market positions has exploded since the 1980s.
Posted inPolitics
Corporate Support of LGBT Rights Is Teetering
The fascist right is finding it easy to bully Target and other companies with a campaign of homophobic terror.
Posted inMoney, Politics, and Power
Ticketmaster Offers to Exploit Concertgoers More Transparently
The ticket broker’s new ‘all-in’ pricing pledge is an effort to stave off antitrust enforcement.
Posted inEnergy and the Environment
Dow’s River
On the Brazos River in Texas, one chemical company reigns supreme.
Posted inLaw and Justice
Biden’s Judicial Nominees Struggle With Antitrust
A review of answers submitted by the nominees reveals a lack of a nuanced understanding of the core legal issues in competition policy.
Posted inHealth and Social Policy
Merck Says Negotiating Drug Prices Is Unconstitutional
The Inflation Reduction Act took minor steps against Big Pharma price-gouging. Merck is outraged.
Posted inHealth and Social Policy
How Big Pharma Rigged the Patent System
Drug patents are supposed to expire in 20 years. Thanks to legal trickery, though, it usually takes a lot longer than that.
